Dyadic International, Inc. (NASDAQ:DYAI) Sees Large Decrease in Short Interest

Dyadic International, Inc. (NASDAQ:DYAI) saw a large decrease in short interest in the month of February. As of February 28th, there was short interest totalling 96,600 shares, a decrease of 19.9% from the February 13th total of 120,600 shares. Based on an average daily volume of 90,700 shares, the short-interest ratio is presently 1.1 days. Currently, 0.5% of the company’s shares are sold short.

Dyadic International Trading Up 3.6 %

Dyadic International stock traded up $0.05 during trading hours on Wednesday, reaching $1.43. 62,830 shares of the company’s stock traded hands, compared to its average volume of 68,917. The company has a debt-to-equity ratio of 1.54, a quick ratio of 5.15 and a current ratio of 5.15. Dyadic International has a fifty-two week low of $0.93 and a fifty-two week high of $2.67. The firm has a market capitalization of $42.31 million, a price-to-earnings ratio of -6.22 and a beta of 0.95. The firm’s 50 day moving average is $1.51 and its 200-day moving average is $1.42.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Truist Financial Corp acquired a new position in Dyadic International during the 4th quarter valued at about $428,000. Inlet Private Wealth LLC acquired a new position in Dyadic International during the 4th quarter valued at about $52,000. Bank of America Corp DE lifted its position in Dyadic International by 16,146.7% during the 4th quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock valued at $47,000 after purchasing an additional 26,965 shares during the period. Jane Street Group LLC acquired a new position in Dyadic International during the 4th quarter valued at about $45,000. Finally, Millennium Management LLC acquired a new position in Dyadic International during the 4th quarter valued at about $28,000. 27.95% of the stock is currently owned by institutional investors and hedge funds.

Dyadic International Company Profile

Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health.